The newly launched next-gen IOL, which has already received CE Mark clearance in the European Union, is designed to provide high-quality vision at both immediate and far distances, which the company touted as “an important first for the monofocal IOL category.”
The Tecnis Eyhance IOL is designed to provide improved intermediate vision when compared with standard aspheric monofocal IOLs, as well as 20/20 distance vision. J&J Vision said that patient-reported outcomes indicated that the Tecnis Eyhance IOL enabled improvements in physical tasks including walking on uneven surfaces and improved engagement in personal activities and hobbies.
“Today, patients with cataracts are forced to make a trade-off decision on their vision when selecting a monofocal intraocular lens. They can have corrected vision at a distance, but require glasses for near and intermediate vision activities, which refers to everything at arm’s length such as computer work or looking at a car speedometer. Tecnis Eyhance IOL offers high quality intermediate as well as distance vision, which is an important advancement to allow patients greater ease in certain activities in their day-to-day lives,” Dr. Oliver Findl of Hanusch Hospital Vienna said in a prepared statement.
The company said it is launching the device initially in the UK, Italy, France, Spain and Germany.
“With the availability of Tecnis Eyhance IOL in Europe, we are proud to deliver another meaningful solution for patients with cataracts. We saw an opportunity to build upon the legacy of the Tecnis Family of IOLs and the proven design of our 1-piece platform to reimagine what was possible with the standard aspheric monofocal IOL,” J&J Vision surgical worldwide prez Tom Frinzi said in a press release.
Last June, J&J Vision said that the FDA approved its iDesign Refractive Studio for planning lasik eye procedures.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.